STOCK TITAN
  1. Home
  2. News
  3. APLM

Apollomics Inc. - APLM STOCK NEWS

Welcome to our dedicated page for Apollomics news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on Apollomics stock.

Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oncology therapies aimed at targeting specific molecular pathways to combat cancer. With a commitment to harnessing the immune system through combination therapies, Apollomics is at the forefront of developing treatments for difficult-to-treat and treatment-resistant cancers.

Originally known as CBT Pharmaceuticals, Apollomics operates with a clear vision of a world without cancer. The company's lead programs include vebreltinib (APL-101), a selective c-Met inhibitor intended for the treatment of non-small cell lung cancer (NSCLC) and other advanced tumors with c-Met alterations, and uproleselan (APL-106), an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy for acute myeloid leukemia (AML).

Apollomics' commitment to rigorous scientific research is evident in their broad pipeline, consisting of nine drug candidates across multiple programs, six of which are currently in clinical stages of development. The company has built strong partnerships and in-licensed assets to advance both preclinical and clinical development programs. These partnerships play a crucial role in enhancing Apollomics' pipeline and expanding the patient populations served.

Recent milestones include:

  • Presentation of interim data from the Phase 2 KUNPENG and SPARTA trials, highlighting the efficacy of vebreltinib in NSCLC patients with MetExon14 skipping mutations.
  • Completion of patient enrollment in the Phase 3 bridging study of uproleselan in China, targeting relapsed or refractory AML.
  • Conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib, making it the first c-Met inhibitor approved for CNS tumors with c-Met alterations.

As the company continues to advance its clinical trials and expand its therapeutic potential globally, Apollomics remains focused on providing transformative treatments that significantly improve patient outcomes.

News

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Rhea-AI Summary
Apollomics Inc. announces the approval of Vebreltinib in China for the treatment of gliomas with MET fusion gene, making it the world's first c-Met inhibitor approved for CNS tumors. The approval is based on a Phase 2/3 trial. The collaboration with Avistone and the global SPARTA trial highlight the potential of Vebreltinib in treating solid tumors with c-Met alterations globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary
Apollomics Inc. presents preclinical data on vebreltinib showing efficacy in treating various tumor types with MET-driver alterations and overcoming resistance in EGFR-positive non-small cell lung cancer at the AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
News

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary
Apollomics Inc. announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research Annual Meeting. The presentations showcase the mechanism of action and anti-tumor activity of vebreltinib in diverse patient-derived tumor models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
none
News

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Rhea-AI Summary
Apollomics Inc. (APLM) reports continued clinical and regulatory progress for vebreltinib and completion of patient enrollment for uproleselan Phase 3 study in China. The company has $37.8 million in cash as of December 31, 2023, with a cash runway till Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.97%
Tags
earnings
-
News

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Rhea-AI Summary
Apollomics Inc. will announce its full year 2023 financial results on March 28, 2024, followed by a conference call and webcast. The management team will discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
earnings
-
News

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Rhea-AI Summary
Apollomics Inc. appoints Matthew Plunkett, Ph.D., as Chief Financial Officer to drive financial strategy and business development. Dr. Plunkett brings over 25 years of experience in the biopharmaceutical sector, enhancing Apollomics' growth and clinical trial progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
management
News

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, Ph.D., and President Sanjeev Redkar, Ph.D., will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The presentation will be accessible via live webcast and a replay will be available. Investors can arrange meetings with the company's management during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.43%
Tags
conferences
-
News

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Rhea-AI Summary
Apollomics Inc. received a notification from Nasdaq stating that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share. The company has 180 days to regain compliance, with the possibility of an additional 180-day period if needed. Failure to regain compliance may lead to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
-
News

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, and President, Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference. The event will take place on January 18, 2024, at 11:00 a.m. ET. The live webcast will be accessible through B. Riley Securities, and an archived replay will be available on the Apollomics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences
News

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) completes enrollment in Phase 3 bridging study for uproleselan in relapsed or refractory acute myeloid leukemia patients in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
clinical trial

FAQ

What is the current stock price of Apollomics (APLM)?

The current stock price of Apollomics (APLM) is $0.114 as of November 4, 2024.

What is the market cap of Apollomics (APLM)?

The market cap of Apollomics (APLM) is approximately 12.4M.

What does Apollomics Inc. do?

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapies, particularly those involving combination treatments to harness the immune system and target specific molecular pathways to fight cancer.

What are Apollomics' lead programs?

Apollomics' lead programs include vebreltinib (APL-101), a c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors, and uproleselan (APL-106), an E-Selectin antagonist used adjunctively with standard chemotherapy for acute myeloid leukemia.

What recent achievements has Apollomics made?

Recent achievements include the presentation of interim data from Phase 2 trials for vebreltinib, completion of patient enrollment in a Phase 3 study for uproleselan, and conditional approval of vebreltinib in China for CNS tumors with c-Met alterations.

How many drug candidates does Apollomics have in its pipeline?

Apollomics currently has a pipeline of nine drug candidates spread across multiple programs, with six candidates in the clinical stage of development.

What is the significance of Apollomics' partnerships?

Apollomics has built strong collaborations and in-licensed assets from various partners, enhancing its development programs and expanding the patient populations served. These partnerships are crucial for advancing their preclinical and clinical development programs.

How does vebreltinib work?

Vebreltinib is a selective c-Met inhibitor that works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth and resistance to certain targeted therapies.

What is uproleselan used for?

Uproleselan is an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia, potentially improving patient outcomes in combination with existing treatments.

What are the key focuses of Apollomics' current research?

Apollomics is focused on advancing clinical trials for their lead programs, vebreltinib and uproleselan, and exploring the potential of these treatments in a variety of tumor types through both monotherapy and combination therapy approaches.

What is the significance of Apollomics' recent conditional approval in China?

The conditional approval of vebreltinib by the NMPA of China for CNS tumors with c-Met alterations highlights the drug's potential to address unmet medical needs in oncology, particularly in treating aggressive brain tumors with specific genetic profiles.

How does Apollomics plan to continue its growth and advancements in oncology treatments?

Apollomics plans to continue its growth by advancing its clinical trials, strengthening partnerships, and exploring new therapeutic areas and combinations to provide transformative treatments for cancer patients globally.

Stock APLM logo
Apollomics Inc.

Nasdaq:APLM

APLM Rankings

#5463 Ranked by Market Cap
N/A Ranked by Dividends

APLM Stock Data

12.38M
108.66M
47.45%
2.15%
0.3%
Biotechnology
Healthcare
Link
United States of America
Foster City